本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届董事 会第三次会议的通知于 2023 年 9 月 18 日以邮件、电话等方式向各位董事发出， 会议于 2023 年 9 月 22 日在公司二楼会议室以现场结合通讯的方式召开。会议应 到董事 10 名，实到董事 10 名，公司部分监事、高级管理人员列席了会议。会议 的召开及表决符合《中华人民共和国公司法》《创业慧康科技股份有限公司章程》 等有关规定。 此次会议由董事长张吕峥先生主持，参会董事认真审议后，依照有关规定通 过以下决议： 一、审议通过了《关于提名公司第八届董事会非独立董事候选人的议案》 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范 性文件及《公司章程》的有关规定，经公司第八届董事会提名，并经董事会提名 委员会进行资格审核，同意选举陈中阳先生为公司第八届董事会非独立董事候选 人（上述候选人简历详见附件），任期自 2023 年第二次临时股东大会审议通过 之 ...

Financial Performance - The company achieved a revenue of 704 million yuan, a year-on-year decrease of 9.74% [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 18 million yuan, down 82.85% year-on-year [2] - In Q2, the company reported a revenue of 355 million yuan, a year-on-year increase of 12.14%, with the medical sector generating 318 million yuan, up 26.80% [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 12 million yuan, a year-on-year increase of 21.32% [2] Market Trends and Orders - The company saw a 20% year-on-year increase in order amounts as of the end of August [3] - New orders worth over 10 million yuan grew by 200% compared to the same period last year, enhancing the company's competitive advantage [3] - The company signed 22 projects for the new generation Hi-HIS management information system, totaling approximately 346 million yuan, with 5 projects delivered in the first half of the year [3] Strategic Developments - The company is actively investing in AI and new generation smart hospital information systems to ensure continuous business expansion [3] - A strategic partnership with Philips is underway to develop the CTasy1.0 electronic medical record product, extending collaboration to medical device sales [3] - The company successfully acquired a regional medical information firm to strengthen its regional advantages [4] Project Distribution - Hospital projects account for approximately 70% to 80% of the company's business, while public health projects make up about 20% to 30% [4] - The overall order ratio for medical institutions and public health projects is approximately 60% and 40%, respectively [4] IoT and Insurance Sector - The company’s IoT business is experiencing growth, with order growth rates surpassing those of medical software [4] - The company has established a strong market presence in the medical insurance sector, participating in multiple provincial projects [5] - Although the revenue from the insurance sector is currently low, the company aims to enhance its presence in municipal and county-level insurance platforms [5] Regulatory Impact - The recent anti-corruption measures in the medical field have not significantly impacted the company's operations, although there were some delays in bidding processes [5]

证券代码：300451 证券简称：创业慧康 公告编号：2023-065 一、回购公司股份的具体情况 截至 2023 年 8 月 31 日，公司尚未开始实施回购。 二、其他说明 公司将严格按照有关规范性文件的要求以及市场情况在回购期限内实施回 购计划，并根据要求及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 创业慧康科技股份有限公司 创业慧康科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于2023年8月22日召开第七 届董事会第三十次会议和第七届监事会第二十四次会议审议通过《关于回购公司 股份方案的议案》，拟使用自有资金以集中竞价交易的方式回购公司部分人民币 普通A股股票，全部用于实施员工持股及、或股权激励计划。本次回购资金总额 不低于人民币3,000万元且不超过人民币6,000万元（含本数），回购价格不超过 10.00元/股。本次回购期限自董事会审议通过回购股份方案之日起不超过12个月。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披 ...

证券代码：300451 证券简称：创业慧康 公告编号：2023-063 创业慧康科技股份有限公司 关于回购公司股份的回购报告书 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、创业慧康科技股份有限公司（以下简称"公司"）拟使用自有资金以集 中竞价交易的方式回购公司部分人民币普通A股股票，全部用于实施员工持股及、 或股权激励计划。本次回购资金总额不低于人民币3,000万元且不超过人民币 6,000万元（含本数），回购价格不超过10.00元/股，按照本次回购金额下限人民 币3,000.00万元，回购价格上限人民币10.00元/股进行测算，回购数量约为300.00 万股，回购股份比例约占公司总股本的0.19%；按照本次回购金额上限人民币 6,000.00万元，回购价格上限人民币10.00元/股进行测算，回购数量约为600万股， 回购股份比例约占公司总股本的0.39%。具体回购股份的数量以回购结束时实际 回购的股份数量为准。本次回购期限自董事会审议通过回购股份方案之日起不超 过12个月。 2、本次回购方案已经公司2023年8月22日召开的第七届董事会第 ...

Business Strategy and Market Position - The company actively responds to new economic and industrial conditions, focusing on market-oriented strategies to enhance product development and technological innovation[1] - The company aims to expand its product line and health service ecosystem to improve profitability and strengthen its market position[1] - The company continues to explore innovative practices in the integration of medical and insurance services, enhancing its unique perspective in the healthcare sector[20] - The company is expanding its innovative business segments to enhance synergy and adapt to the rapidly changing healthcare market[68] - The company faces risks related to market competition and the need for effective resource allocation to support its business expansion plans[86] Research and Development - During the reporting period, the company trained and fine-tuned its AI model from 6 billion parameters to 13 billion parameters, utilizing over 130,000 drug knowledge entries and 1,000 disease knowledge entries[19] - The company invested 160 million yuan in R&D, resulting in 7 new invention patents and 43 new software copyrights[35] - The company is focusing on the integration of AI technology in healthcare, having signed a strategic agreement with Zhejiang University to promote AI applications in the medical field[38] - The company adheres to a principle of "independent research and development as the main focus" and has developed competitive core technologies[140] Product and Service Development - The company has successfully implemented its clinical decision support system (CDSS) based on GPT algorithms in multiple hospitals, enhancing healthcare service delivery[19] - The company has developed a comprehensive smart health solution to assist local governments in building regional health information systems[17] - The company has launched an intelligent medical assistant that has been successfully operational in hospitals, improving patient care processes[19] - The company has established a cloud-based technology and architecture foundation for its products, enabling comprehensive business cloudification[26] - The company has developed over 300 proprietary products to meet the information needs of hospitals and health management institutions[130] Financial Performance - The company's operating revenue for the reporting period was approximately ¥704.39 million, a decrease of 9.74% compared to the previous year[52] - Net profit attributable to shareholders was ¥24,007,310.44, down 76.35% year-on-year[106] - The net profit after deducting non-recurring gains and losses was ¥18,437,052.56, reflecting an 82.85% decline compared to the previous year[106] - The basic earnings per share decreased by 71.43% to ¥0.02[106] - The total assets at the end of the reporting period were ¥5,685,625,734.47, a decrease of 1.69% from the end of the previous year[106] Cash Flow and Financial Stability - The net cash flow from operating activities improved by 9.41%, amounting to approximately -¥171.33 million[52] - The net increase in cash and cash equivalents was approximately -¥394.13 million, a decline of 55.29% due to increased cash outflows from financing activities[60] - The company maintains a low debt-to-asset ratio and emphasizes cash flow management and risk control[135] - The company’s cash and cash equivalents decreased from approximately 1.48 billion yuan at the beginning of the year to about 1.09 billion yuan by June 30, 2023[143] Strategic Partnerships and Collaborations - The company has established strategic cooperation with Lianren Health to enhance digital health integration and innovation[63] - The company is collaborating with Philips on the CTasy1.0 electronic medical record product, with the outpatient process version completed and ongoing development for emergency and inpatient process versions[38] Market Expansion and Service Coverage - The company has accumulated approximately 300 million resident health records, maintaining a leading position in the healthcare information industry with over 7,000 industry users[46] - The company has established 11 regional marketing service centers and 15 provincial marketing service centers, covering over 30 provinces, cities, and autonomous regions in China[48] - The company's SAAS internet hospital platform has connected nearly 1,500 institutions and registered over 40,000 doctors, with a year-on-year growth of 13.5% in new online consultations and total prescriptions[64] Investment and Project Management - The total investment amount for the reporting period was ¥77,257,659.66, a decrease of 36.47% compared to the previous year[175] - The company acquired a 51% stake in Lanzhou Yuanteng Software Technology Co., Ltd. for ¥51,000,000.00[175] - The total amount of committed investment projects is CNY 131,760.96 million, with an adjusted total investment amount of CNY 128,877.04 million[184] Risk Management and Governance - The company is implementing post-merger management to mitigate goodwill impairment risks associated with acquisitions[91] - The company plans to enhance management systems and integrate resources to mitigate operational risks from mergers and acquisitions[99] - The company is focusing on employee stock ownership and equity incentive plans as part of its strategic initiatives[165]

北京市天元律师事务所 关于创业慧康科技股份有限公司 2023 年第一次临时股东大会的法律意见 京天股字（2023）第 473 号 致：创业慧康科技股份有限公司 创业慧康科技股份有限公司（以下简称"公司"）2023 年第一次临时股东大会 （以下简称"本次股东大会"）采取现场投票与网络投票相结合的方式召开，现场会 议于 2023 年 8 月 25 日 14:30 在杭州市滨江区长河街道越达巷 92 号创业智慧大厦 二楼会议室召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派 本所律师参加本次股东大会现场会议，并根据《中华人民共和国公司法》《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则（2022 年修 订）》（以下简称"《股东大会规则》"）以及《创业慧康科技股份有限公司章程》（以 下简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程序、出席现 场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《创业慧康科技股份有限公司第七届董事 会第二十九次会议决议公告》《创业慧康科技股份有限公司第七届监事会第二十三 ...

证券代码：300451 证券简称：创业慧康 公告编号：2023-051 创业慧康科技股份有限公司 2023年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议日期和时间：2023 年 8 月 25 日（星期五）下午 14:30 （2）网络投票日期和时间：2023 年 8 月 25 日。其中，通过深圳证券交易 所交易系统进行网络投票的具体时间为：2023 年 8 月 25 日 9:15-9:25、9:30-11:30， 13:00-15:00。通过深圳证券交易所互联网投票系统投票的具体时间为：2023 年 8 月 25 日 9:15 至 2023 年 8 月 25 日 15:00 的任意时间。 2、召开地点：杭州市滨江区长河街道越达巷 92 号创业智慧大厦二楼会议。 特别提示： 1、本次股东大会无新增、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开； 4、为尊重中小投资者利益，提高中小投资者 ...

特别提示： 1、公司第一大股东葛航先生与公司第二大股东飞利浦（中国）投资有限公 司（以下简称"飞利浦"）拥有公司表决权的股份比例较为接近，其他股东持股 比例较为分散。故截至目前，无任何单一股东能控制公司股东大会，无任何单一 股东依其可实际支配的上市公司股份表决权足以对公司股东大会的决议产生重 大影响。 证券代码：300451 证券简称：创业慧康 公告编号：2023-050 创业慧康科技股份有限公司 关于公司无控股股东及无实际控制人的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 3、合计持股 3%以上股东张吕峥先生和浙江鑫粟科技有限公司及其一致行 动人联合推荐：张吕峥先生和胡燕女士； 4、公司独立董事由第七届董事会提名的蔡家楣先生、刘海宁先生、谭青女 士（会计专业人士）、凌云先生当选。 2、2023 年 8 月 25 日，经创业慧康科技股份有限公司（以下简称"公司"） 2023 年第一次临时股东大会决议，公司完成第八届董事会的换届。本届董事会 非独立董事七人，分别由第一大股东葛航先生推荐的应晶先生和葛波休先生、第 二大股东飞利浦推荐的 KWOK WAI AN ...

创业慧康科技股份有限公司独立董事 关于公司无控股股东且无实际控制人的独立意见 根据《公司法》《证券法》《上市公司治理准则》《上市公司独立董事规则》 及《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件规定 及《创业慧康科技股份有限公司章程》（以下简称"《公司章程》"）《独立董事 工作制度》，作为创业慧康科技股份有限公司（以下简称"公司"或"创业慧康"） 的独立董事，本着认真、负责的态度，基于独立、审慎、客观的立场，我们对公 司认定将处于无控股股东且无实际控制人状态事项发表独立意见如下： 根据《公司法》《上市公司收购管理办法》《深圳证券交易所创业板股票上 市规则》等相关法律法规对上市公司控股股东及实际控制人的认定依据，结合公 司目前股东现状情况，目前公司股权较为分散，拥有公司 5%以上表决权的股东 不存在其他一致行动关系或一致行动安排，公司目前不存在持股 50%以上或可以 实际支配上市公司股份表决权超过 30%的单一股东，不存在能够决定公司董事会 半数以上成员选任或对公司股东大会的决议产生重大影响的单一股东，不存在能 够单 ...

证券代码：300451 证券简称：创业慧康 公告编号：2023-054 创业慧康科技股份有限公司 关于公司董事会、监事会完成换届选举及 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开 公司 2023 年第一次临时股东大会，会议选举产生了公司第八届董事会成员和第 八届监事会非职工代表监事成员。并于同日召开第八届董事会第一次会议、第七 届监事会第一次会议，分别审议通过了选举董事长、董事会专门委员会委员、监 事会主席及聘任公司高级管理人员和证券事务代表等相关议案。截至本公告披露 日，公司董事会、监事会的换届选举工作已完成，现将相关情况公告如下： 一、公司第八届董事会组成情况 1、董事长：张吕峥先生 2、非独立董事：张吕峥先生、胡燕女士、应晶先生、葛波休先生、KWOK WAI ANDY HO（何国伟）先生和叶江先生 3、独立董事：蔡家楣先生、刘海宁先生、谭青女士、凌云先生 公司第八届董事会成员（简历见附件）均具备担任上市公司董事的任职资格， 未受过中国证监会及其他有关部门的处罚和证券交易所 ...